ImmunityBio
IBRX
58 hedge funds and large institutions have $113M invested in ImmunityBio in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 14 closing their positions.
97% more capital invested
Capital invested by funds: $57.6M → $113M (+$55.7M)
71% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 14
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
1.55% less ownership
Funds ownership: 19.72% → 18.16% (-1.6%)
3% less funds holding
Funds holding: 60 → 58 (-2)
27% less call options, than puts
Call options by funds: $1.49M | Put options by funds: $2.04M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.96M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$531K |
| 3 |
State Street
Boston,
Massachusetts
|
+$510K |
| 4 |
AA
ALPS Advisors
Denver,
Colorado
|
+$320K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$230K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wildcat Capital Management
New York
|
-$4.73M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.57M |
| 3 |
Renaissance Technologies
New York
|
-$1.71M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.2M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$481K |
IBRX Hedge Fund Activity: Q2 2017 in Review
58 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2017, worth a combined $113M — up 97% from $57.6M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of IBRX and 13 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 24 added.
The largest buyer was BlackRock, adding an estimated $2.96M. The largest seller was Wildcat Capital Management, cutting an estimated $4.73M.
- 58 institutional investors held ImmunityBio (IBRX) as of Q2 2017, down from 60 in Q1 2017.
- Funds reported $113M of ImmunityBio stock for Q2 2017, up 97% quarter-over-quarter.
- 13 funds opened new ImmunityBio positions in Q2 2017 and 14 closed out, a net change of -1 holder.
- The largest ImmunityBio buyer in Q2 2017 was BlackRock, an estimated $2.96M added.
- The largest ImmunityBio seller in Q2 2017 was Wildcat Capital Management, an estimated $4.73M sold.
Based on aggregated 13F filings for Q2 2017.